Bioelectronic Devices Capture and Release Tumor Cells for Early Cancer Diagnosis
|
By LabMedica International staff writers Posted on 11 Sep 2023 |

Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the main cause of cancer-related deaths. Metastasis occurs when a cancer cell detaches from the initial tumor, travels through the bloodstream and lymphatic system, and invades other parts of the body. Collecting these circulating tumor cells non-invasively is crucial for understanding cell biology, as well as for cancer diagnosis, prognosis, and drug development. Traditional methods for gathering these cells in a usable form are time-consuming, given that the concentration of these cells in the bloodstream is incredibly low compared to other cell types.
Now, a group of researchers at the University of the Basque Country (UPV/EHU, Leioa, Spain) has designed a bioelectronic device that could revolutionize this process. The device featuring gold electrodes coated with a smart polymer not only captures but also releases cells in a controllable, non-destructive manner, while simultaneously tracking these activities through standard electrical readings. This is seen as a foundational step toward creating universal systems for early cancer detection. Previous biosensors designed for this purpose were less than ideal because they damaged cells during the capture and release process. To address this, the team integrated smart materials with bioelectronics, which involves the use of carbon-based semiconductors, for more accurate and less harmful cell capture and release mechanisms.
In their preliminary tests, the researchers did not use real patient samples but instead relied on commercial cells sustained in culture media. The results demonstrated that the device successfully captured and released these cells. The team is now in the process of customizing the polymer to interact specifically with different types of cells. Currently, the device is being used on esophageal cancer patient samples. Its role is to selectively accumulate cancer cells, making it easier to determine their concentration in the sample.
“We wanted to come up with a device capable of concentrating cancer cells in order to detect their concentration,” said Janire Sáez, Ikerbasque research professor in the UPV/EHU’s Microfluidics Cluster Group. These are the first steps towards developing platforms for cancer screening. This could be a good step forward because they generally involve low-cost technologies and can be mass-produced. The idea is to use this type of technology for early cancer diagnosis.”
Related Links:
UPV/EHU
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read more
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








